Moxeza®
Moxifloxacin 0.5% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis
Instill one drop in the affected eye 3 times a day for 7 days
OFF-LABELNot in the FDA label for this product
Endophthalmitis prophylaxis at cataract surgery, intracameral
0.03 mL (150 mcg) of undiluted 0.5% solution injected into the anterior chamber at the end of phacoemulsification.
RCT · n=3,640 · single-center
Prospective randomized partially masked single-center trial, 3,640 eyes: acute endophthalmitis within 6 weeks in 1 of 1,818 injected eyes (0.05%) vs 7 of 1,822 uninjected (0.38%), P = 0.035, with no difference in corrected distance acuity, endothelial cell density, IOP or central corneal thickness; both arms also received topical 0.5% moxifloxacin and 0.1% dexamethasone postoperatively. A retrospective before-and-after registry of 617,453 surgeries at 10 Aravind hospitals found 0.02% (64/314,638) with prophylaxis vs 0.07% (214/302,815) without (P < 0.001); that is a registry comparison, not a randomized one. Both studies injected an unpreserved 0.5% topical solution; the xanthan gum vehicle is not the product studied intracamerally.
Bacterial keratitis
Trial regimen: 0.5% solution instilled hourly for 48 hours, then tapered by clinical response, in ulcers 2 to 8 mm.
RCT · n=61 · underpowered
Randomized three-arm trial, 61 patients (20 on moxifloxacin 0.5%, 21 on gatifloxacin 0.3%, 20 on fortified cefazolin 5% plus tobramycin 1.3%): 93% healed overall, no significant difference in mean time to heal (P = 0.98), and treatment failure in 1 of 20 vs 2 of 20 on fortified antibiotics. The authors' stated conclusion is that the study failed to find a difference, which at 20 patients per arm and 62% culture positivity is not a demonstration of equivalence. The report does not name the formulation used.
Contraindications
History of hypersensitivity to moxifloxacin, to other quinolones, or to any component of the formulation.
3 mL bottle, 0.5% solution, 5 mg moxifloxacin base per mL
Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs. Its antibacterial action results from inhibition of topoisomerase II (DNA gyrase), an essential enzyme involved in the replication, transcription and repair of bacterial DNA, and of topoisomerase IV, which plays a key role in partitioning chromosomal DNA during bacterial cell division. Its mechanism differs from that of macrolides, aminoglycosides and tetracyclines, and there is no cross-resistance between moxifloxacin and those classes. Cross-resistance has been observed between systemic moxifloxacin and some other quinolones.
Warnings & Precautions
- Hypersensitivity reactions: Serious and occasionally fatal anaphylactic reactions have been reported with systemically administered quinolones, including moxifloxacin, some after the first dose and some with cardiovascular collapse, loss of consciousness, angioedema, airway obstruction, dyspnea, urticaria and itching. If an allergic reaction occurs, discontinue use. Serious acute reactions may require immediate emergency treatment, with oxygen and airway management as clinically indicated.
- Resistant organism overgrowth: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
- Contact lens wear: Not appropriate in the presence of signs or symptoms of bacterial conjunctivitis.
Common Side Effects
The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing, in approximately 1% to 6% of patients. Nonocular adverse events reported at a rate of 1% to 4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral dosing in rats and monkeys and IV dosing in rabbits through organogenesis produced no adverse maternal or fetal effects at clinically relevant doses; embryo-fetal findings (reduced fetal weight, delayed skeletal ossification, and in rabbits abortion and malformations) appeared only at systemic exposures hundreds to thousands of times the human AUC at the ophthalmic dose, several of them maternally toxic.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production. Transfer into milk occurs in lactating rats after oral dosing, and systemic levels after topical ocular use are low.
Safety and effectiveness established in all ages, including neonates.